Advicenne Pharma intends to aggressively pursue the development of a  portfolio of original molecules and markers for diagnosis and treatment of CNS Orphan diseases including autism, feeding behaviours dysfunctions and neurodegenerative disorders.
Advicenne’s drugs rely on state-of-the-art scientific works and led to the development of new clinical strategies for targeted diseases.
Advicenne Pharma will mainly focus in actively selecting drug candidates for clinical development through a process including:

•  Acquisition of new product candidates after extensive due diligence 
•  Identification of potential risks and weaknesses
•  Enhancement of the attractiveness of the project by completing the existing preclinical package of data as necessary
• IP reinforcement
• Enhancement of the regulatory toxicology and pharmacological package including adequate pharmaco-kinetic studies
• Building an integrated clinical development plan: pre clinical and primary clinical indications
• Collaborative agreement with high quality partners